Zinc α-2-glycoprotein Regulates Melanin Production by Normal and Malignant Melanocytes  by Hale, Laura P.
Zinc a-2-glycoprotein Regulates Melanin Production by
Normal and Malignant Melanocytes
Laura P. Hale
Department of Pathology and the Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, U.S.A.
Zinc a-2-glycoprotein is secreted by a variety of
normal and malignant epithelial cells and over-
expression by tumors has been implicated in cancer
cachexia. To investigate biologic properties of zinc
a-2-glycoprotein further, stable transfectants of
recombinant human zinc a-2-glycoprotein were cre-
ated in the B16F10 murine melanoma cell line. Both
B16-recombinant human zinc a-2-glycoprotein
clones with strong expression of zinc a-2-glyco-
protein and vector-transfected B16 cells treated with
exogenous zinc a-2-glycoprotein had decreased
melanin production in vitro. Furthermore, B16-
recombinant human zinc a-2-glycoprotein clones
formed amelanotic tumors in vivo, despite their
melanin production in vitro. Although no qualitative
differences in tyrosinase mRNA expression could be
detected by reverse transcription±polymerase chain
reaction, B16-recombinant human zinc a-2-glyco-
protein tumors had decreased levels of tyrosinase
protein and minimal tyrosinase activity. Puri®ed zinc
a-2-glycoprotein also decreased tyrosinase activity in
vector-transfected B16 tumor sections in vitro. Taken
together, these studies demonstrate that zinc a-2-
glycoprotein inhibits melanin production by B16
melanoma cells via post-transcriptional effects on
tyrosinase protein. As zinc a-2-glycoprotein
decreases melanin synthesis more strongly in vivo
than in vitro, however, it is likely that zinc a-2-glyco-
protein affects melanin synthesis through indirect
mechanisms as well. Zinc a-2-glycoprotein also
inhibits melanin production by melan-A primary
melanocytes in vitro. As zinc a-2-glycoprotein is
normally produced by epidermal keratinocytes, these
studies raise the possibility that epidermal-derived
zinc a-2-glycoprotein may play a part in normal
regulation of melanin production in vivo, in addition
to its previously described role in cancer cachexia.
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Z
inc a-2-glycoprotein (ZAG) is a plasma glycoprotein
that was named for its electrophoretic mobility and for
its ability to be precipitated by zinc salts (Burgi and
Schmid, 1961). It is a member of the immunoglobulin
gene superfamily and has a three-dimensional struc-
ture that is highly homologous to major histocompatibility complex
class I and II molecules (Sanchez et al, 1999). ZAG has been
detected immunohistochemically in normal secretory epithelial
cells of breast, prostate, and liver, in salivary, bronchial,
gastrointestinal, and sweat glands (Tada et al, 1991; Hale et al,
2001), and in normal strati®ed epithelia, including epidermis (Lei et
al, 1997; Brysk et al, 1997b). ZAG mRNA is expressed in a similar
distribution (Freije et al, 1991). Consistent with its production by
secretory epithelium, ZAG is present in most body secretions and
constitutes 2.5% and 30% of the proteins present in saliva and
seminal ¯uid, respectively (Poortmans and Schmid, 1968). Plasma
or serum levels of ZAG have been described to vary with age, with
reported values ranging from 0.9±3.5 mg per dl (fetal) to 7.8±
12.1 mg per dl (young adults) to 18±30 mg per dl (normal men
aged 51±70) (Jirka et al, 1974, 1978; Hale et al, 2001). ZAG
accumulates in breast cyst ¯uids to 30±50-fold plasma concentra-
tion (Bundred et al, 1987; Sanchez et al, 1997) and is overexpressed
in 40±50% of breast carcinomas (Bundred et al, 1987; Sanchez et al,
1992; Diez-Itza et al, 1993). We have recently shown that ZAG is
produced in large amounts by most prostate carcinomas, resulting
in elevated serum levels of ZAG in prostate cancer patients (Hale et
al, 2001). ZAG has also been identi®ed in epidermal malignancies,
including squamous and Merkel cell carcinomas, with lesser
expression in basal cell carcinomas (Brysk et al, 1997b; Lei et al,
1997). Little is known about mechanisms regulating ZAG
expression by tumors; however, ZAG production by normal
epithelial tissues was shown to be increased by treatment with
androgens, corticosteroids, interferon-g, or transforming growth
factor-b (Lopez-Boado et al, 1994; Brysk et al, 1997a,b).
The normal functions of ZAG are unclear; however, ZAG has
been isolated from the urine of human cancer patients with
cachexia and can function as a lipid-mobilizing factor. ZAG
puri®ed from human or mouse serum or human cancer patient
urine induces lipolysis resulting in glycerol release and also increases
lipid utilization in both human and mouse adipocytes (Hirai et al,
1998). ZAG activates a guanosine triphosphate-dependent adeny-
late cyclase activity on adipocyte membranes, increasing cellular
cyclic adenosine monophosphate levels (Hirai et al, 1998). This may
potentially lead to activation of multiple cellular pathways;
however, further details of its mechanism of action are unknown.
Using a panel of murine tumors, Todorov et al (1998) quantitated
ZAG production in vitro and showed that cachexia induction in
mice bearing these tumors in vivo correlated with their ZAG
Manuscript received June 7, 2001; revised March 1, 2002; accepted for
publication March 7, 2002.
Reprint requests to: Dr. Laura P. Hale, Box 3712, DUMC, Duke
University Medical Center, Durham, NC 27710, U.S.A.
Email: laura.hale@duke.edu
0022-202X/02/$15.00 ´ Copyright # 2002 by The Society for Investigative Dermatology, Inc.
464
production. Whether ZAG has additional biologic activities in
addition to cachexia induction is unknown.
To investigate biologic properties of ZAG further, stable
transfectants of recombinant human (rh)ZAG were created in the
B16F10 murine melanoma cell line. The effect of ZAG transfection
on melanin production was determined in vitro and in vivo. The
effect of exogenous ZAG on melanin production by parent B16
cells and melan-A primary melanocytes was determined. Finally,
the effect of ZAG on tyrosinase expression and activity was
determined. Taken together, these studies show that ZAG inhibits
melanin production in both normal and malignant melanocytes.
Mechanisms include post-transcriptional effects on tyrosinase
protein, with the potential for additional indirect effects. These
studies have identi®ed a previously unknown biologic function of
ZAG and contribute to our knowledge of the pathways regulating
pigment production in melanoma and other tumor and normal
tissues.
MATERIALS AND METHODS
Construction of ZAG-producing murine cell lines A full-length
human ZAG cDNA, including the endogenous secretory signal sequence
was cloned from human liver using reverse transcription±polymerase
chain reaction (reverse transcription±PCR) and primers corresponding to
bp 3±21 and bp 938±920 (GenBank accession no. D90427). The
construct sequence was veri®ed by automated DNA sequencing, using
the Duke University Cancer Center DNA Sequencing Shared Resource.
Full length human ZAG cDNA was inserted into the pCDNA3.1(±)
Myc-His eukaryotic expression vector (Invitrogen, Carlsbad, CA) using
restriction enzyme digestion and adapter ligation to ensure in-frame
insertion relative to the myc and 6-His 3¢ epitope tags. Epitope-tagged
recombinant human ZAG constructs were transfected into B16F10 (B16)
murine melanoma cells (American Type Culture Collection, Rockville,
MD). Stable transfectants were obtained by G418 selection then cloned
by limited dilution. Parent and transfected cell lines were grown in
Dulbecco's minimal Eagle's medium + 10% fetal bovine serum at 37°C
in an atmosphere supplemented with 5% CO2. Culture supernatants
were analyzed in triplicate for expression of ZAG by antigen capture
enzyme-linked immunosorbent assay using anti-ZAG monoclonal
antibody (MoAb) 1B5 (Sanchez et al, 1997) as capture antibody. Bound
rhZAG was detected using biotinylated anti-ZAG MoAb 1H4 (Sanchez
et al, 1997), streptavidin±horseradish peroxidase conjugate (Jackson
ImmunoResearch Laboratories, West Grove, PA), and diaminobenzidine
substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD).
Standard curves were constructed using high-performance liquid
chromatography-puri®ed rhZAG, quantitated by A280 (Burgi and
Schmid, 1961). The sensitivity of the assay was 10 pg per ml. Enzyme-
linked immunosorbent assay results were con®rmed by sodium dodecyl
sulfate±polyacrylamide gel electrophoresis and western blot detection of
epitope-tagged rhZAG with the predicted molecular weight of 46 kDa
using anti-ZAG MoAb 1B5 and/or the India His-Probe nickel-
horseradish peroxidase reagent (Pierce, Rockford, IL) speci®c for the 6-
His epitope tag. Vector-transfected cell populations (B16-V) were also
derived and used as controls. B16-V cells showed no evidence of
reactivity with the anti-human ZAG MoAb used in either antigen
capture enzyme immunoassays or western blots, although B16 cells have
been shown to express small amounts of murine ZAG (Todorov et al,
1998 and data not shown).
Analysis of melanin production Melanin content of B16 cell lines
was determined by microscopic evaluation of eosin-stained
cytocentrifuge preparations. To be considered heavily melanized, cells
had to contain > 10 melanosome specks visible at a magni®cation of
3 100 or > 1 macro-melanosome. The majority of cells considered
heavily melanized had at least a ``salt and pepper'' appearance with many
melanosome specks present. Melanin production by B16 cell lines was
also determined by absorbance measurements (600 nm) of phenol red-
free culture supernatants.
Melan-A primary murine melanocytes (a kind gift from Dr Vincent
Hearing, National Institutes of Health) were propagated in RPMI1640,
10% fetal bovine serum, 2 mM glutamine, 100,000 U penicillin per l,
100 mg streptomycin sulfate per l, 200 nM tetradecanoyl phorbol acetate
and seeded onto six-well plates for measurements of melanin production.
After 96 h of culture with various concentrations of ZAG, media was
aspirated and cells were washed once in phosphate-buffered saline, then
solubilized in 200 ml 1 M NaOH, and pipetted repeatedly to homo-
genize. Melanin absorbance was determined at 600 nm. Melanin content
of melan-A cells was also determined by microscopic evaluation of
eosin-stained cytocentrifuge preparations.
Animal and tissue studies All animal experimentation was conducted
under a protocol approved by the Duke University Institutional Animal
Care and Use Committee. rhZAG or vector-transfected B16 tumor cells
(2 3 105) were implanted subcutaneously in the ¯ank in groups of ®ve
syngeneic female C57BL/6 mice. Mice were weighed then killed and
serum was obtained at 21 d postimplantation, just prior to tumor-related
death. Tumor size was measured using calipers. The concentration of
tumor-produced human ZAG in the serum was measured by antigen
capture enzyme-linked immunosorbent assay as described above. Each
serum sample was analyzed in quadruplicate for at least two independent
dilutions and results were averaged. Samples of tumors for histologic
analysis were snap-frozen in Tissue-Tek OCT compound (Sakura,
Torrance, CA) and stored at ±80°C.
Immunoperoxidase staining for tyrosinase protein was performed on
frozen sections of B16 tumors using aPEP7 rabbit polyclonal anti-
serum (a kind gift of Dr Vincent J. Hearing) (Jimenez et al, 1991; Aroca
et al, 1993). Other reagents included biotinylated goat anti-rabbit
secondary antibody, avidin±biotin±horseradish peroxidase complexes
(VectaStainABC; Vector Laboratories, Burlingame, CA) and Nova Red
substrate (Vector Laboratories). Negative controls to ensure the speci®-
city of staining included use of normal rabbit serum on B16 tumors and
use of aPEP7 on 4T1 murine breast carcinoma tumors that do not
produce melanin.
Ferrous ion uptake and L-DOPA histochemical stains were performed
on frozen sections of B16 tumors as described (Sheehan and Hrapchak,
1987). The ferrous-ion uptake stain is speci®c for preformed melanin,
generating a blue color in proportion to the amount of melanin present.
The L-DOPA stain provides an assay for tyrosinase activity. In vivo,
tyrosinase catalyzes the oxidation of tyrosine to DOPA (3,4-dihydrox-
yphenylalanine) as well as the oxidation of DOPA to melanin through
intermediate steps. When fresh frozen tissue sections are incubated with a
buffered solution of DOPA, a melanin-like pigment is deposited in
proportion to the degree of tyrosinase activity present (Sheehan and
Hrapchak, 1987). A Nuclear Fast Red counterstain was used for both
ferrous ion uptake and L-DOPA histochemical stains.
For western blot determination of tyrosinase protein levels, protein
extracts were prepared from ®ve 20 mm frozen sections of B16-V or
B16-rhZAG tumors or from cultured melan-A cells using 10 mM Tris
pH 8.0, 150 mM NaCl, 1% Triton X-100, with protease inhibitors
(Complete Mini Ethylenediamine Tetraacetic Acid-free Protease
Inhibitor tablets, Roche Molecular Biochemicals, Indianapolis, IN). The
protein content of tumor extracts was determined using the BCA assay
(Pierce). Equal amounts of protein by weight for tumor extracts or
corresponding to equivalent numbers of cells for melan-A cells were
analyzed by sodium dodecyl sulfate±polyacrylamide gel electrophoresis,
transferred to nitrocellulose, and reacted with aPEP7 anti-tyrosinase
rabbit polyclonal anti-serum or control rabbit serum followed by goat
anti-rabbit immunoglobulin coupled to horseradish peroxidase. Bound
antibody was detected by chemiluminescence (SuperSignal West Pico
Chemiluminescence Substrate, Pierce).
RNA was isolated from tumor tissue using an RNeasy kit (Qiagen,
Valencia, CA). Two micrograms of RNA was reversed transcribed using
SuperScript (Gibco BRL, Rockville, MD) and the resulting cDNA was
subjected to PCR for 15, 20, 25, and 30 cycles using Platinum Taq
(Gibco BRL). Primers were selected to cross intron±exon boundaries
and did not amplify genomic DNA. Primer sequences for tyrosinase
(415 bp) were 5¢ CAG ATC TCT GAT GGC CAT 3¢ and 5¢ GGA
TGA CAT AGA CTG AGC 3¢ (bp 101±118 and bp 515±498, GenBank
accession no. NM_011661) and for GAPDH (214 bp) were
5¢ TCG TCC CGT AGA CAA AAT G 3¢ and 5¢ TGA CAA GCT
TCC CAT TCT C 3¢ (bp 31±49 and bp 244±227, GenBank accession
no. M32599). Products were analyzed on ethidium-bromide-stained gels
and ZAG to GAPDH product ratio was determined at 15, 20, 25, and
30 cycles for each sample.
Puri®cation of ZAG rhZAG was puri®ed from supernatant of
rhZAG-transfected 293 human kidney epithelial cells using a Ni-NTA
af®nity column (Qiagen) speci®c for the His epitope tag or by
concentration from serum-free media (293 SFM II, Gibco BRL) using a
30 kDa molecular weight cut-off ®lter. Sodium dodecyl sulfate±
polyacrylamide gel electrophoresis gels followed by western blotting
con®rmed that the protein in these ZAG preparations was highly
immunoreactive with anti-ZAG MoAb.
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Tumor necrosis factor (TNF)-a assays TNF-a protein was detected
by antigen capture enzyme immunoassay using the Duo-Set TNF-a kit
(R&D Systems, Minneapolis, MN) according to the manufacturer's
protocol. The sensitivity of this assay is 15 pg per ml. TNF-a mRNA
was detected by reverse transcription±PCR assays using primers
corresponding to bp 301±318 and bp 527±510 of the GenBank accession
no. NM_013693 sequence (5¢ TGT CTA CTG AAC TTC GGG 3¢ and
5¢ TCT TTG AGA TCC ATG CCG 3¢, respectively). The 560 murine
astrocytoma cell line transfected with TNF-a (Sampson et al, 1997) was
used as a control to insure appropriate detection of both TNF-a mRNA
and protein under the conditions used.
RESULTS
ZAG overproduction decreases melanin production by B16
cells in vitro In vitro, B16 melanoma cells typically produce
melanin such that the culture supernatant turns visually black soon
after cultures become con¯uent. Melanin production by B16-
rhZAG clones 3G12 and 10XA8 that expressed ZAG at high levels
was compared with that by B16-V cells. A clear and consistent
decrease in the rate of melanin accumulation could be seen within
cultures of B16-rhZAG vs B16-V cells by visual inspection of
media soon after cultures reached con¯uence (Fig 1A). These
visual differences could no longer be discerned at later time points
when melanin accumulation was maximal (not shown). Eosin-
stained cytocentrifuge preparations of B16-rhZAG clones 3G12
and 10XA8 and B16-V cells obtained from logarithmically growing
cultures were also examined for the presence of the cytoplasmic
dark specks that are indicative of melanin production. The amount
of melanin present within the cytoplasm of ZAG-transfected cells
was signi®cantly decreased when compared with vector-transfected
cells (Fig 1B±D). Fewer B16-rhZAG cells contained visible
melanin specks and less total melanin was present in the
cytoplasm of B16-rhZAG cells that contained melanin specks. In
particular, the percentage of heavily melanized cells was
signi®cantly reduced in both B16-rhZAG clones analyzed relative
to B16-V cells (16 6 1% and 14 6 2%, mean 6 SD, respectively,
for 3G12 and 10XA8 vs 45 6 2% for B16-V; p < 0.0003). Thus
high level expression of ZAG decreases melanin synthesis by
individual B16-rhZAG cells.
ZAG overexpression decreases the rate of melanin
accumulation in vitro To investigate further the effects of
ZAG overexpression on melanin accumulation during culture,
serial measurements of both melanin and rhZAG present in the
media from B16-rhZAG clones 3G12 and 10XA8 and B16-V cells
were performed as a function of time. As shown in Fig 2A, the
concentration of ZAG peaks at 47 h postcon¯uence and decreases
thereafter. Although 3G12 cells produce melanin in vitro, cultures
do not turn visibly black until 51 h postcon¯uence, compared with
42 h for 10XA8 and B16-V cells. Melanin accumulation in the
media of the 3G12 cell line remains consistently below that of B16-
V cells for all time points analyzed (Fig 2B). Decreases in melanin
production by B16-rhZAG clone 10XA8 compared with B16-V
cells were not detectable at the time points analyzed in these
experiments. Whether the increasing black color of the media from
24 to 58 h postcon¯uence results from increased melanin synthesis
and/or from increased secretion of melanin into the culture
medium is unknown. Eosin-stained cytocentrifuge preparations of
3G12, 10XA8, and B16-V cells made 68 h postcon¯uence show
relatively few melanin granules (not shown) compared with those
made from logarithmically growing cells, suggesting that melanin
secretion may increase postcon¯uence; however, these cells are
viable and proliferate and synthesize melanin when passaged. The
A600 of the melanin-containing media decreases by the 68 h point
(Fig 2B), most likely as a result of further oxidation or breakdown
of previously produced melanin. This decreased absorbance
suggests that oxidized melanin and/or melanin breakdown
products contribute less to the measured A600 as compared with
newly synthesized or secreted melanin. Our observation that the
A600 of melanin-containing media from B16-V cultures decreases
during cell-free culture at 37°C support this interpretation (data not
shown).
Exogenous ZAG decreases melanin synthesis by B16-V cells
in vitro The above studies suggest that ZAG overproduction is
suf®cient to decrease melanin synthesis by B16-rhZAG melanoma
cells that are genetically engineered to overexpress ZAG. To
determine whether similar effects could be obtained when ZAG is
supplied exogenously, B16-V cells were treated with puri®ed
rhZAG at concentrations ranging from 10 to 100 mg per ml. As
shown in Fig 3, addition of exogenous rhZAG also inhibited
melanin production by B16-V cells in vitro in a concentration-
dependent manner.
ZAG expression turns off melanin synthesis by B16 tumor
cells in vivo In addition to producing melanin in culture, B16
cells also typically produce melanin in vivo and B16 tumors thus
appear black when grown in mice. The growth and melanin
production by B16-rhZAG clone 3G12 and B16-V cells in vivo
were next compared in groups of ®ve syngeneic mice. B16-rhZAG
Figure 1. B16-rhZAG clones demonstrate decreased melanin production in vitro. (A) Visual inspection of media in stacked culture plates
shows decreased melanin production by B16-rhZAG clones 10XA8 (lower plate) and 3G12 (middle plate) compared with B16-V cells (top plate)
approximately 24 h after achieving con¯uence. Eosin-stained cytocentrifuge preparations of B16-rhZAG clones 3G12 (C) and 10XA8 (D) also show
decreased numbers of heavily melanized cells relative to B16-V cells (B) when examined during logarithmic growth.
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tumors showed signi®cantly decreased growth at 21 d compared
with B16-V tumors (mean tumor volume 6 SEM:
289 6 74 mm3 vs 943 6 62 mm3, p < 0.0002). rhZAG could
be detected in the serum of mice with B16-rhZAG but not B16-V
tumors [156 6 70 ng per ml (mean 6 SD) vs undetectable].
Increased ZAG production by B16-rhZAG tumors was suf®cient
to cause a mean weight loss of 15% in the group bearing rhZAG-
transfected tumors (ending weights: B16-vector 20.6 6 1.1 g;
B16-ZAG 17.5 6 0.8 g; p = 0.001), which remained signi®cant
when corrected for differences in tumor volumes; however,
although B16-rhZAG clone 3G12 can produce (albeit decreased
amounts of) melanin in vitro, tumors derived from these cells show
no evidence of melanin production in vivo and thus appear white
grossly (not shown). Histochemical staining using the more
sensitive ferrous ion uptake stain similarly shows almost total lack
of melanin production in B16-rhZAG tumors, as indicated by lack
of blue reaction product (Fig 4A,B). This marked decrease in
melanin production by B16-rhZAG cells in vivo contrasts with the
comparatively modest decrease in melanin production seen in these
cells in vitro.
ZAG affects tyrosinase activity at a post-transcriptional
level Melanin synthesis is controlled in part by regulating the
levels and/or activity of the tyrosinase enzyme that is required for
the ®nal stages of melanin synthesis. To investigate further the
mechanism by which tumor-produced ZAG affects melanin
synthesis, the presence of mRNA encoding tyrosinase in B16-
rhZAG and B16-V cells grown in vitro and tumors grown in vivo
were analyzed by reverse transcription±PCR. The amount of
tyrosinase product relative to GAPDH product was similar in
melanin-producing B16-V tumors vs amelanotic B16-rhZAG
tumors grown in vivo as well as in B16-rhZAG vs B16-V cells
grown in vitro (not shown). This suggests that the decrease in
melanin production by ZAG-transfected B16 cells most likely
occurs by a mechanism other than by transcriptional inhibition of
tyrosinase mRNA production.
To determine how ZAG affects tyrosinase enzyme activity,
frozen sections of B16-rhZAG and B16-V tumors were incubated
with the tyrosinase substrate L-DOPA. Although strong tyrosinase
activity can be observed in B16-V tumors (black color, Fig 4C),
very little tyrosinase activity is present in B16-rhZAG tumors
(Fig 4D). B16-rhZAG tumors show clear evidence of reactivity
with aPEP7 polyclonal anti-tyrosinase antibody in immunoperox-
idase assays (red color, Fig 4F), but their reactivity is decreased
relative to B16-V tumors (Fig 4E). Neither B16-V nor B16-
rhZAG tumors react with normal rabbit serum alone (Fig 4G,H),
and aPEP7 is nonreactive with 4T1 breast carcinoma tumors that
do not produce melanin (not shown), further con®rming the
speci®city of the aPEP7 reagent. To study further the relation
between tyrosinase protein levels and tyrosinase enzyme activity,
western blots were also performed using extracts from three
different B16-V and B16-rhZAG tumors. Speci®c bands corres-
ponding to tyrosinase protein were present in all six tumors studied.
The amount of tyrosinase, however, was qualitatively decreased in
at least two of the three B16-rhZAG tumors tested (data not
shown). No reactivity was seen in duplicate blots reacted with
control rabbit serum or in lanes containing extracts of 4T1-rhZAG
breast cancer tumors that do not express tyrosinase. Thus, ZAG
overexpression appears to decrease but does not abrogate the
expression of tyrosinase protein in B16 tumors, when examined
both immunohistologically and by western blot.
The almost total lack of tyrosinase activity in B16-rhZAG
tumors (Fig 4D) despite the presence of immunohistologically
detectable tyrosinase protein (Fig 4F and data not shown)
suggested that ZAG may also affect tyrosinase activity by other
Figure 3. Exogenous ZAG decreases melanin synthesis by B16-V
cells in vitro. Ten to 100 mg per ml exogenous rhZAG inhibits the
production and/or secretion of melanin into culture supernatant by B16-
V cells. Results shown are representative of four experiments performed.
Figure 2. Decrease in melanin production by B16 cells in vitro
correlates with ZAG overexpression. Cells (5 3 105) were plated in
11 ml of phenol red-free media per 100 mm dish 96 h prior to
beginning absorbance measurements and reached con¯uence
approximately 72 h after plating. ZAG concentrations peaked at 47 h
postcon¯uence for 3G12 cells (A). Spectrophotometric analysis of culture
supernatants (B) shows a signi®cant lag in melanin production by B16-
rhZAG clone 3G12, with peak A600 at 58 h postcon¯uence. Decreased
melanin production by B16-rhZAG clone 10XA8 was not detectable at
the time points analyzed in these experiments. Media appeared black
visually when A600 was > 0.100.
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mechanisms, in addition to affecting levels of tyrosinase protein. To
determine whether ZAG could directly affect the activity of
tyrosinase protein, frozen sections of B16-V tumors were incubated
with varying concentrations of exogenous rhZAG prior to the
addition of the tyrosinase substrate L-DOPA. Sections incubated
with 1±8 mg rhZAG per ml had a 25±50% decrease in color
development with L-DOPA (data not shown). ZAG concentra-
tions less than 1 mg per ml gave no visible inhibition of the L-
DOPA reaction. Taken together, the immunohistochemical and L-
DOPA studies clearly demonstrate that ZAG decreases melanin
synthesis in B16 melanoma cells by post-transcriptional effects on
the level and activity of tyrosinase protein.
ZAG inhibits melanin synthesis by normal melanocytes To
determine whether ZAG also affects melanin synthesis by normal
melanocytes, the melanin content of melan-A primary murine
melanocytes treated with varying concentrations of ZAG was
determined. As shown in Fig 5(A), ZAG decreased melanin
synthesis by melan-A cells in a concentration-dependent fashion,
with a mean inhibition of 68% at 150 mg per ml exogenous ZAG.
The number of heavily melanized cells seen in eosin-stained
cytocentrifuge preparations was decreased by ZAG treatment
(Fig 5C,D). Finally, western blots using aPEP7 anti-tyrosinase
antibody (Fig 5B) demonstrated that 150 mg ZAG per ml
markedly decreased levels of tyrosinase protein in melan-A cells,
similar to its effect in B16 cells. Thus these studies indicate that
ZAG has similar effects on melanin production in both normal and
malignant melanocytes.
DISCUSSION
The data in the study show that B16 tumor cells that are either
transfected to express ZAG strongly or treated with exogenous
ZAG have decreased melanin production in vitro. B16 tumors
strongly expressing ZAG also have decreased growth and form
amelanotic tumors in vivo. Despite qualitatively similar levels of
tyrosinase mRNA expression, ZAG-transfected B16 (B16-rhZAG)
tumors had decreased levels of tyrosinase protein and minimal
tyrosinase activity. Puri®ed ZAG also decreased melanin produc-
tion by B16-V cells in vitro and decreased tyrosinase activity in B16-
V tumor sections in vitro. Taken together, these results demonstrate
that ZAG inhibits melanin synthesis in B16 cells at a post-
transcriptional level. ZAG, however, appears to decrease tumor cell
growth and melanin synthesis in vivo more strongly relative to its
effects in vitro, suggesting that ZAG may also act through other
indirect mechanisms in vivo. ZAG similarly decreases melanin
production in primary murine melanocytes in vitro.
It is important to note that moderate to high levels of ZAG are
required to achieve signi®cant inhibition of melanin synthesis. B16
cells are normally highly melanized despite their production of low
levels of murine ZAG (Todorov et al, 1998; data not shown). The
numbers of heavily melanized cells are decreased similarly in ZAG-
transfected 10XA8 and 3G12 cultures (Fig 1C,D). The accumu-
lation of melanin in the media, however, decreases much more in
3G12 cultures that produce approximately twice the ZAG
produced by 10XA8 cultures (Figs 1A and 2A,B). Indeed,
although visual decreases in secretion of melanin into the media
Figure 4. ZAG overexpression decreases
melanin synthesis in vivo through post-
transcriptional effects on tyrosinase protein.
A ferrous ion uptake stain shows abundant
melanin production (blue color) in B16-V cells
(A), with near total absence of reactivity in
murine tumors derived from B16-rhZAG clone
3G12 (B). Incubation of frozen tumor sections
with L-DOPA shows strong tyrosinase activity
(black color) in B16-V tumors (C) compared with
an almost total lack of tyrosinase activity in B16-
rhZAG tumors (D). Immunoperoxidase staining
with aPEP7 anti-serum speci®c for tyrosinase
showed decreased reactivity (red color) with B16-
rhZAG tumors (F) relative to B16-V tumors (E).
No staining is seen in B16-V (G) or B16-rhZAG
(H) tumors using normal rabbit serum as a
negative control.
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by 10AX8 can be observed at some time points compared with
vector-transfected cells (Fig 1A), secretion of melanin as measured
by A600 of media at other time points is not signi®cantly decreased
in 10XA8 (Fig 2B). These observations may indicate that a
threshold amount of ZAG may be required for simultaneously
decreasing both melanogenesis and melanin secretion. Our obser-
vation that ZAG-transfected tumor cells that make melanin in vitro
are amelanotic in vivo (Fig 4B), however, demonstrates that the
concentration of ZAG required to inhibit melanin synthesis is
readily achieved at tumor sites in vivo. A variety of tumor types
derived from secretory and strati®ed epithelium, including
squamous cell carcinomas, have been shown to produce measurable
amounts of ZAG (Bundred et al, 1987; Sanchez et al, 1992; Diez-
Itza et al, 1993; Lei et al, 1997, 1999; Hale et al, 2001). We have
previously shown that tumor-produced ZAG can contribute to
elevated systemic (serum) ZAG levels in prostate cancer patients
(Hale et al, 2001). Whether ZAG-secreting tumors can raise serum
ZAG to concentrations that will inhibit melanin synthesis at sites
remote from the tumors will require further study.
Higher levels of exogenous rhZAG are required to achieve
similar levels of tyrosinase inhibition when compared with ZAG
production by rhZAG-transfected cells. This may re¯ect very high
local concentrations adjacent to rhZAG-producing cells or may
indicate that ZAG also affects tyrosinase activity through indirect
mechanisms that require metabolism or changes in gene expression,
protein synthesis or half-life of ZAG or other proteins. The in vivo
studies that show essentially complete inhibition of melanogenesis
in tumors of ZAG-transfected B16 cells in vivo compared with only
partial inhibition in vitro also suggest that ZAG may inhibit melanin
synthesis by indirect mechanisms. This may occur through effects
on other cells that are present in vivo in addition to direct effects that
ZAG has on the tumor cells themselves in vitro. Alternatively, in vivo
growth conditions may have generated and selected for new tumor
cell clones with resistance to ZAG and reduced production of
melanin by alternative mechanisms. Further study of tumors
derived from ZAG-transfected B16 cells will be required to
distinguish between these mechanisms.
The data in this study show that ZAG expression also inhibits the
growth of B16-rhZAG tumors in vivo. ZAG has previously been
shown to inhibit the proliferation of the Tu-138 oral squamous cell
carcinoma cell line, when the cells are plated directly on to
immobilized ZAG (Lei et al, 1999). Whether the decreased
proliferation results from increased tumor cell differentiation as
hypothesized by Lei et al (1999) will require further study using
tumors in which cellular differentiation can be objectively meas-
ured. It does, however, imply that ZAG has additional biologic
effects on tumor cells beyond stimulating lipolysis and melanin
synthesis.
a-melanocyte stimulating hormone has previously been shown
to regulate the expression of tyrosinase mRNA, in addition to
having other neuroimmunomodulatory effects (Lipton and Catania,
1997; Ottaviani et al, 1997). Whereas a-melanocyte stimulating
hormone was not measured directly, the RT-PCR studies
presented here provide no evidence for ZAG-induced changes in
tyrosinase gene transcription. They do show a clear and direct effect
of ZAG on level and activity of tyrosinase protein; however,
decreased melanin synthesis by melanoma tumor cells could
potentially arise from inhibition in multiple pathways. Whether
ZAG in¯uences melanin production by B16 melanoma cells by
additional mechanisms in addition to effects on tyrosinase protein
will be the subject of future studies.
As TNF-a has previously been shown to inhibit melanin
synthesis by human primary melanoma and B16 melanoma cells
(Swope et al, 1991; Martinez-Esparza et al, 1998, 1999), it was
important to determine whether ZAG acted via a mechanism
involving TNF-a. TNF-a was undetectable in the supernatant of
both B16-V and B16-rhZAG cells cultured in vitro and TNF-a
mRNA could not be detected in either B16-V or B16-rhZAG cells
by reverse transcription±PCR (data not shown). Small amounts of
TNF-a ``spiked'' into the supernatant from B16-V and B16-
rhZAG cells could be detected quantitatively, however, indicating
that these supernatants do not contain substances that interfere with
the detection of TNF-a protein. Taken together, these ®ndings
suggest that ZAG inhibits melanin synthesis by B16 cells via a
TNF-a-independent mechanism. Whether ZAG is thus a TNF
mimetic or whether ZAG- and TNF-a-dependent pathways share
downstream effector pathways remain to be determined. The data
in this study show that ZAG regulates melanin production in B16
melanoma cells, a widely used model of melanocyte function. The
generalizability of the anti-melanogenic functions of ZAG is further
demonstrated by its inhibitory effect on melanogenesis by melan-A
normal murine melanocytes in vitro. ZAG is produced by normal
epidermal keratinocytes, where its expression increases with cellular
differentiation (Lei et al, 1997). Others have previously demon-
strated that keratinocyte-derived factors in¯uence melanocyte
behavior, including melanocyte proliferation, dendricity, and total
melanin production (Gordon et al, 1989). Thus taken together, the
work presented in this study suggests that epidermal-derived ZAG
Figure 5. Exogenous ZAG inhibits melanin production by melan-
A primary melanocytes in vitro. The indicated amount of ZAG was
added to six-well plates seeded with 0.165 3 106 melan-A cells and
cultured for 96 h prior to harvesting the cells for assessment of melanin
production by absorbance at 600 nm, histologic examination, and
western blot. (A) ZAG inhibited melanin production in a concentration-
dependent manner as determined by absorbance measurements of cell
lysates. Data shown are the mean 6 range of two independent
experiments. Three additional experiments that used differing numbers of
cells and different ZAG concentrations also showed a concentration-
dependent inhibition of melanin production. (B) A western blot detected
with aPEP7 anti-tyrosinase anti-serum demonstrates that tyrosinase
protein is decreased in melan-A cells treated with 150 mg ZAG per ml
as compared with phosphate-buffered saline-treated control cells. (C,D)
Eosin-stained cytocentrifuge preparations show decreased numbers of
heavily melanized cells in ZAG-treated cultures (150 mg per ml) (D) vs
control melan-A cultures (C).
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may play a part in normal regulation of melanin production in vivo,
in addition to its previously described role in cancer cachexia.
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